Milford, CT, June 25, 2015 --(PR.com
)-- Produced by The Morgan Leary Vaughan Fund, and funded by The Petit Family Foundation, Speaking of NEC is a series of one-on-one conversations with relevant Necrotizing Enterocolitis (NEC) experts—neonatologists, clinicians and researchers—that highlights current prevention, diagnosis, and treatment strategies for NEC, and the search for a cure.
Episode 4: 100% Human Milk Diet—Perspectives from Dr. Martin Lee
This episode features Dr. Martin Lee, Vice President of Clinical Research and Development at Prolacta Bioscience. During this episode, Dr. Lee provides a comprehensive overview of a 100% or exclusive human milk diet in the prevention of NEC in extremely premature babies, those weighing less than 1250 grams (2 pounds 12 ounces) and who have the greatest risk for developing the disease. He discusses:·
• His transition from the blood industry to Prolacta, which developed of the world’s first human milk-based human milk fortifier
• What constitutes a 100% or exclusive human milk diet
• The clinical evidence showing a 70% reduction in NEC, an 8-fold reduction in surgical NEC, and a 4-fold reduction in morality through the use of exclusive human milk diet
• The importance of safety in the breast milk industry, including Prolacta’s rigorous product testing and donor safety profiles which parallel blood industry standards.
Episode 4 launches on Sunday, June 28, 2015 at noon EDT, and will be available to listen to, or download, at morgansfund.org or on iTunes.
This episode was produced in part by the TeacherCast Educational Broadcasting Network. For more information about Speaking of NEC or The Morgan Leary Vaughan Fund, visit morgansfund.org.
About The Morgan Leary Vaughan Fund, Inc.
The Morgan Leary Vaughan Fund (Morgan’s Fund) is an all-volunteer, public charity dedicated to Necrotizing Enterocolitis (NEC). Its mission is to promote public awareness about NEC and the potentially devastating effects it can have on preemies and their families, and to advance research to prevent, diagnose, treat, and ultimately, cure NEC. Named after Morgan, it celebrates his survival, courage and strength.
Morgan and his twin brother were born at 28 weeks, one day gestation — nearly three months early — each weighing less than 2.5 pounds. At four days old, Morgan developed NEC and lost approximately 20% of his small intestine. Morgan not only survived but has also thrived since his bout with NEC. This is his family’s way of paying it forward.
About The Petit Family Foundation
The Petit Family Foundation honors the memories of Jennifer Hawke-Petit, Hayley Elizabeth Petit and Michaela Rose Petit by continuing the kindness, idealism and activism that defined their lives. The Foundation’s funds are given to foster the education of young people, especially women in the sciences; to improve the lives of those affected by chronic illnesses; and to support efforts to protect and help those affected by violence.
About Prolacta Bioscience
Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk.® The company pioneered the development of human milk-based Neonatal Nutritional Products to meet the needs of critically ill, premature infants in the NICU. Prolacta leads the industry in the quality and safety of nutritional products made from breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk. For more information please visit www.prolacta.com.